Drugs / Levomilnacipran ER
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02288325 | Nov 2014 → Sep 2016 | major depressive disorder | Forest Laboratories | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Levomilnacipran ER | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02288325 ↗ |
| Route | Oral | “Levomilnacipran ER taken orally at 40, 80 or 120 mg once daily.” NCT02288325 ↗ |